Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Researchers also found that about one-third of teens undergoing weight-loss surgery had a body mass index (BMI) of more than ...

Zepbound is also used to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. An interaction can occur because one substance causes another substance to have a different ...

In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea in adults with obesity. In addition, LLY filed tirzepatide for heart failure ...

Our Bureau, Mumbai Monday, May 12, 2025, 14:45 Hrs [IST] ...